Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB
CAIN457M2301E1
Phase 3 small_molecule active
Quick answer
Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB for Hidradenitis suppurativa is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Hidradenitis suppurativa
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active